Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY Interest Expense

Cost of servicing the company's debt during the period.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $15K a year earlier. Trailing-twelve-month interest expense was $55K. Over 3 fiscal years it compounded at +127.9% a year.

Context

  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $13.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$71K+0.0% YoY
LTMMar 2026
$55K-16.7% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+0.0%——
3-year CAGR+127.9%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
71K USD
Year-over-year change
+0.0%
4-year CAGR
-42.0%

Interest Expense vs competitors

How UNCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.7% is the highest of 4, against a peer median of -47.5%.
  • Over three fiscal years its annual growth of +127.9% compares with a peer median of +29.3%.
UNCY Competitors
Interest Expense for UNCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CBUSCibus, Inc.LTM Mar 2026$17.98M USD-47.5%+641.6%419.6%
VXRTVaxart, Inc.LTM Mar 2026$2.33M USD-26.3%+29.3%0.9%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$55K USD-16.7%+127.9%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$1.94K CAD-84.1%-51.1%0.0%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 USD———
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$0 USD——0.0%
IMUXImmunic, Inc.LTM Mar 2026$0 USD———
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD———
Peer median (excluding UNCY) —-47.5%+29.3%0.5%

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0951K675K00
Cost of Revenue0000572K
Gross Profit0951K675K0(572K)
Gross Margin—100.0%100.0%——
Research & Development6.08M12.44M12.9M20.01M9.12M
Selling, General & Admin2.9M6.57M8.55M12.1M20.4M
Operating Expenses8.98M19M21.45M32.12M28.95M
Depreciation & Amortization13K161K284K428K572K
EBITDA(9.38M)(17.89M)(30.18M)(36.23M)(25.91M)
EBITDA Margin—-1881.3%-4470.8%——
Operating Income(8.98M)(18.05M)(20.77M)(32.12M)(29.52M)
Operating Margin—-1898.2%-3077.6%——
Interest Income00615K1.26M1.01M
Interest Expense628K6K82K71K71K
Other Income / Expenses(1.04M)(6K)(9.77M)(4.61M)2.96M
Income Before Tax(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Pre-Tax Margin—-1898.8%-4525.0%——
Income Tax Expense00000
Net Income(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Net Margin—-1898.8%-4525.0%——
EPS (Basic)(8.60)(1.20)(1.28)(5.60)(1.67)
EPS (Diluted)(8.60)(1.20)(1.28)(5.60)(1.67)
Weighted Avg Shares1.17M1.51M2.45M6.7M158.87M
Weighted Avg Shares (Diluted)1.17M1.51M2.45M6.7M158.87M

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.